Correction of anemia in uremic mice by genetically modified peritoneal mesothelial cells

Kidney International

Volumn 63, Issue 6, 2003, Pages 2103-2112

  Einbinder, Tom ^b   Sufaro, Yuval ^b   Yusim, Igor ^b   Byk, Gerardo ^b   Passlick Deetjen, Jutta ^b   Chaimovitz, Cidio ^b   Douvdevani, Amos ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b NONE

Author keywords

Erythropoietin; Mesothelial cells; Peritoneal dialysis

Indexed keywords

COLLAGEN; CYCLOSPORIN A; ERYTHROPOIETIN; FIBRONECTIN; GELATIN; LAMININ; LIPOSOME; POLY DEXTRO LYSINE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL GROWTH; CELL ISOLATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DIALYSATE LEVEL; DNA MODIFICATION; EFFLUENT; EPO GENE; EVALUATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HEMATOCRIT; MESOTHELIUM CELL; MOUSE; NEPHRECTOMY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RETROVIRUS; TRANSGENE; UREMIA;

EID: 0038527357     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00014.x     Document Type: Article

References (37)

1. CRYSTAL RG: Transfer of genes to humans: Early lessons and obstacles to success. Science 270:404-410, 1995
2. JACKMAN RW, STAPLETON TD, MASSE EM, et al: Enhancement of the functional repertoire of the rat parietal peritoneal mesothelium in vivo: Directed expression of the anticoagulant and antiinflammatory molecule thrombomodulin. Hum Gene Ther 9:1069-1081, 1998
3. SETOGUCHI Y, JAFFE HA, CHU CS, et al: Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 10:369-377, 1994
4. MURPHY JE, RHEINWALD JG: Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy. Hum Gene Ther 8:1867-1879, 1997
5. NAGY JA, SHOCKLEY TR, MASSE EM, et al: Mesothelial cell-mediated gene therapy: feasibility of an ex vivo strategy. Gene Ther 2:393-401, 1995
6. NAGY JA, SHOCKLEY TR, MASSE EM, et al: Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther 2:402-410, 1995
7. DIAZ C, SELGAS R, CASTRO MA, et al: Ex vivo proliferation of mesothelial cells directly obtained from peritoneal effluent: Its relationship with peritoneal antecedents and functional parameters. Adv Perit Dial 14:19-24, 1998
8. DI PAOLO N, SACCHI G, VANNI L, et al: Autologous peritoneal mesothelial cell implant in rabbits and peritoneal dialysis patients. Nephron 57:323-331, 1991
9. DESFORGES JF: Anemia in uremia. Arch Intern Med 126:808-811, 1970
10. ECKARDT KU: After 15 years of success-perspectives of erythropoietin therapy. Nephrol Dial Transplant 16:1745-1749, 2001
11. NAFFAKH N, HENRI A, VILLEVAL JL, et al: Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci USA 92:3194-3198, 1995
12. OSBORNE WR, RAMESH N, LAU S, et al: Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 92:8055-8058, 1995
13. DESCAMPS V, BLUMENFELD N, BEUZARD Y, et al: Keratinocytes as a target for gene therapy. Sustained production of erythropoietin in mice by human keratinocytes transduced with an adenoassociated virus vector. Arch Dermatol 132:1207-1211, 1996
14. DALLE B, PAYEN E, REGULIER E, et al: Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts. Gene Ther 6:157-161, 1999
15. BARTHOLOMEW A, PATIL S, MACKAY A, et al: Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 12:1527-1541, 2001
16. STYLIANOU E, JENNER LA, DAVIES M, et al: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 37:1563-1570, 1990
17. MORI T, YAMAMOTO K, OHTA T, et al: A high-level and regulatable production system for recombinant glycoproteins using a human interferon-alpha promoter-based expression vector. Gene 144:289-293, 1994
18. MORGENSTERN JP, LAND H: Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18:3587-3596, 1990
19. MARKOWITZ DG, GOFF SP, BANK A: Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments. Trans Assoc Am Physicians 101:212-218, 1988
20. BYK G, DUBERTRET C, ESCRIOU V, et al: Synthesis, activity, and structure-Activity relationship studies of novel cationic lipids for DNA transfer. J Med Chem 41:229-235, 1998
21. KITAMURA T, TANGE T, TERASAWA T, et al: Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 140: 323-334, 1989
22. CHUNATIN A, FERRIS JEB: Experimental renal insufficiency produced by partial nephrectomy. Arch Inter Med 49:767-787, 1932
23. HAMAMORI Y, SAMAL B, TIAN J, et al: Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 95:1808-1813, 1995
24. LEAVESLEY DI, STANLEY JM, FAULL RJ: Epidermal growth factor modifies the expression and function of extracellular matrix adhesion receptors expressed by peritoneal mesothelial cells from patients on CAPD. Nephrol Dial Transplant 14:1208-1216, 1999
25. BETJES MG, TUK CW, STRUIJK DG, et al: Adherence of staphylococci to plastic, mesothelial cells and mesothelial extracellular matrix. Adv Perit Dial 8:215-218, 1992
26. PORTER CD, LUKACS KV, BOX G, et al: Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J Virol 72:4832-4840, 1998
27. THEMIS M, FORBES SJ, CHAN L, et al: Enhanced in vitro and in vivo gene delivery using cationic agent complexed retrovirus vectors. Gene Ther 5:1180-1186, 1998
28. PITARD B, AGUERRE O, AIRIAU M, et al: Virus-sized self-assembling lamellar complexes between plasmid DNA and cationic micelles promote gene transfer. Proc Natl Acad Sci USA 94:14412-14417, 1997
29. BYK G, SOTO J, MATTLER C, et al: Novel non-viral vectors for gene delivery: Synthesis of a second-generation library of mono-functionalized poly-(guanidinium) amines and their introduction into cationic lipids. Biotechnol Bioeng 61:81-87, 1998
30. FASBENDER A, ZABNER J, CHILLON M, et al: Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 272: 6479-6489, 1997
31. SOMMER B, RINSCH C, PAYEN E, et al: Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. Mol Ther 6:155-161, 2002
32. RINSCH C, REGULIER E, DEGLON N, et al: A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 8:1881-1889, 1997
33. RATCLIFFE PJ, MAXWELL PH, PUGH CW: Beyond erythropoietin: The oxygen sensor. Nephrol Dial Transplant 12:1842-1848, 1997
34. OSADA S, EBIHARA I, SETOGUCHI Y, et al: Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 55:1234-1240, 1999
35. PALMER TD, ROSMAN GJ, OSBORNE WR, et al: Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 88:1330-1334, 1991
36. GERRARD AJ, HUDSON DL, BROWNLEE GG, et al: Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 3:180-183, 1993
37. REGULIER E, SCHNEIDER BL, DEGLON N, et al: Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther 5:1014-1022, 1998